Want to see AU:IME full AI Analyst Report?
IME Stock Chart & Stats
AU$0.40
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.40
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.21 - AU$0.47
Previous CloseN/A
Volume202.98K
Average Volume (3M)41.77K
Market Cap
AU$19.04M
Enterprise ValueAU$18.89
Total Cash (Recent Filing)AU$3.30M
Total Debt (Recent Filing)AU$566.32K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding54,395,714
10 Day Avg. Volume23,052
30 Day Avg. Volume41,775
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.59M
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationSustained revenue acceleration to 10% in 2025 signals stronger product-market fit and expanding customer adoption. Over 2-6 months this underpins durable top-line momentum, improves leverage potential on fixed costs, and provides a runway to translate scale into improved operating performance.
Conservative LeverageVery low debt-to-equity leaves the company with meaningful financial flexibility and lower solvency risk. This structural strength supports capacity to fund growth initiatives, withstand revenue cyclicality, and pursue strategic investments or M&A without forcing dilutive or distressed financing.
Positive Operating And Free Cash FlowThe shift to positive operating and free cash flow reflects improving cash conversion and operational discipline. Durable cash generation reduces reliance on external funding, enables reinvestment in growth or margin improvement, and materially improves the company's financial optionality.
Bears Say
Persistent Losses And Negative Operating MarginOngoing net losses and a negative operating margin indicate the business has not yet achieved consistent profitability. This structural weakness limits retained earnings, hampers ROE improvement, and constrains the firm’s ability to self-fund expansion without sustained margin recovery or structural cost changes.
Sharp Gross Margin DeteriorationA material drop in gross margin suggests either pricing pressure, higher delivery costs, or adverse mix shifts. This directly impairs long-term profitability potential: even with revenue growth, lower gross margins require larger scale or permanent cost reductions to restore sustainable operating profits.
Negative Returns And Cash VolatilityNegative ROE shows the firm is destroying shareholder capital, while uneven cash conversion raises forecasting risk. Together these durable issues limit capital allocation flexibility, increase the need for external financing if growth is pursued, and prolong the path to consistent, self-sustaining profitability.
ImExHS Limited News
IME FAQ
What was ImExHS Limited’s price range in the past 12 months?
ImExHS Limited lowest share price was AU$0.20 and its highest was AU$0.47 in the past 12 months.
What is ImExHS Limited’s market cap?
ImExHS Limited’s market cap is AU$19.04M.
When is ImExHS Limited’s upcoming earnings report date?
ImExHS Limited’s upcoming earnings report date is Aug 31, 2026 which is in 23 days.
How were ImExHS Limited’s earnings last quarter?
ImExHS Limited released its earnings results on Feb 26, 2026. The company reported AU$0.002 earnings per share for the quarter, beating the consensus estimate of -AU$0.015 by AU$0.017.
Is ImExHS Limited overvalued?
According to Wall Street analysts ImExHS Limited’s price is currently Overvalued.
Does ImExHS Limited pay dividends?
ImExHS Limited does not currently pay dividends.
What is ImExHS Limited’s EPS estimate?
ImExHS Limited’s EPS estimate is -0.05.
How many shares outstanding does ImExHS Limited have?
ImExHS Limited has 54,395,714 shares outstanding.
What happened to ImExHS Limited’s price movement after its last earnings report?
ImExHS Limited reported an EPS of AU$0.002 in its last earnings report, beating expectations of -AU$0.015. Following the earnings report the stock price went up 9.756%.
Which hedge fund is a major shareholder of ImExHS Limited?
Currently, no hedge funds are holding shares in AU:IME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImExHS Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IME Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
ImExHS Limited
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―






